The use of G-CSF is recommended by the American Society of Clinical Oncology and the National Comprehensive Cancer Network in patients receiving cytotoxic agent treatments to reduce the risk of neutropenia and its complications, enabling safe and effective chemotherapy dose intensity [31]. This evidence concerns the gene CSF3 and Decreased total neutrophil count.